Developing treatments for pulmonary arterial hypertension

Abstract

Developing new treatments for pulmonary arterial hypertension (PAH) is a challenge. We have enjoyed success with regulatory approvals for three drug classes-prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. But we have also seen some disappointing results, for example, from studies with vasoactive intestinal polypeptide… (More)
DOI: 10.4103/2045-8932.109961

Topics

2 Figures and Tables